

产品名称: ZLN005

产品别名: ZLN005

生物活性:																		
Description	ZLN005 is a potent activator of peroxisome proliferator-activated receptor- γ coactivator-1 α (PGC-1 α)[1].																	
IC₅₀ & Target	Peroxisome proliferator-activated receptor- γ coactivator-1 α [1]																	
In Vitro	ZLN005 (2.5-20 μ M; 24 hours) activates AMPK in a dose-dependent manner[1].																	
	Western Blot Analysis[1]																	
	Cell Line: L6 myotubes																	
	Concentration: 2.5, 5, 10, 20 μ M																	
	Incubation Time: 24 hours																	
Result: Dose-dependent activation of AMPK.																		
In Vivo	ZLN005 (15 mg/kg; p.o.; per day for 4 weeks) decreases random blood glucose and fasting blood glucose levels over 4 weeks compared with lean mice[1].																	
	Animal Model: Eight-week-old db/db mice[1]																	
	Dosage: 15 mg/kg																	
	Administration: Oral administration; per day for 4 weeks																	
	Result: Random blood glucose and fasting blood glucose levels decreased significantly over 4 weeks compared with lean mice.																	
Solvent&Solubility	In Vitro: DMSO : 22 mg/mL (87.88 mM; Need ultrasonic)																	
	<table border="1"> <thead> <tr> <th rowspan="2">Preparing Stock Solutions</th> <th>Solvent Mass Concentration</th> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td>1 mM</td> <td>3.9946 mL</td> <td>19.9728 mL</td> <td>39.9457 mL</td> </tr> <tr> <td>5 mM</td> <td>0.7989 mL</td> <td>3.9946 mL</td> <td>7.9891 mL</td> </tr> <tr> <td>10 mM</td> <td>0.3995 mL</td> <td>1.9973 mL</td> <td>3.9946 mL</td> </tr> </tbody> </table>	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	1 mM	3.9946 mL	19.9728 mL	39.9457 mL	5 mM	0.7989 mL	3.9946 mL	7.9891 mL	10 mM	0.3995 mL	1.9973 mL	3.9946 mL
	Preparing Stock Solutions		Solvent Mass Concentration	1 mg	5 mg	10 mg												
		1 mM	3.9946 mL	19.9728 mL	39.9457 mL													
	5 mM	0.7989 mL	3.9946 mL	7.9891 mL														
	10 mM	0.3995 mL	1.9973 mL	3.9946 mL														
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。																	
	In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂: ——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶																	
	1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline Solubility: 2.2 mg/mL (8.79 mM); Suspended solution; Need ultrasonic 此方案可获得 2.2 mg/mL (8.79 mM)的均匀悬浊液, 悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例, 取 100 μ L 22.0 mg/mL 的澄清 DMSO 储备液加到 400 μ L PEG300 中, 混合均匀 向上述体系中加入 50 μ L Tween-80, 混合均匀; 然后继续加入 450 μ L 生理盐水定容至 1 mL。																	
	2.请依序添加每种溶剂: 10% DMSO→ 90% (20% SBE- β -CD in saline)																	

	<p>Solubility: ≥ 2.2 mg/mL (8.79 mM); Clear solution</p> <p>此方案可获得 ≥ 2.2 mg/mL (8.79 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例, 取 100 μL 22.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中, 混合均匀。</p> <p>3.请依序添加每种溶剂: 10% DMSO \rightarrow 90% corn oil</p> <p>Solubility: 2.2 mg/mL (8.79 mM); Precipitated solution; Need ultrasonic</p> <p>此方案可获得 2.2 mg/mL (8.79 mM)</p> <p>以 1 mL 工作液为例, 取 100 μL 22.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中, 混合均匀。</p>
<p>References</p>	<p>[1]. Zhang LN, et al. Novel small-molecule PGC-1α transcriptional regulator with beneficial effects on diabetic db/db mice. Diabetes. 2013 Apr;62(4):1297-307.</p>



源叶生物